Fig. 3.

Change in (A) lymphocyte count over time and (B) mHLA-DR antigen expression over time.

Mean (SD), BL, baseline; mAb, monoclonal antibody; mHLA-DR, monocyte human leukocyte antigen-DR subtype; SD, standard deviation. A, Patient numbers in the 480 mg group: baseline to Day 21 (n = 5) and Day 28 (n = 4). Patient numbers in the 960 mg group: baseline to Day 4 (n = 8), Day 7 to Day 14 (n = 6), Day 21 (n = 4), and Day 28 (n = 5). B, Patient numbers in the 480 mg group: baseline to Day 14 (n = 5) and Day 28 (n = 4). Patient numbers in the 960 mg group: baseline to Day 3 (n = 7), Day 7 (n = 6), and Day 14 to Day 28 (n = 5). Lymphocyte count baseline data were obtained within 48 h before the administration of nivolumab. mHLA-DR baseline data were obtained approximately 30 min before the administration of the study drug. The mHLA-DR antigen expression reference line is at 8,000 mAb/cell and the lymphocyte count reference line is at 1,100/μL.